Business Wire

CO-LIQID-INC.

Share
Case Study: Durham University Deploys Liqid Composable Infrastructure to Study Universe’s 14 Billion-Year History with Adaptive, More Sustainable Infrastructure

LIQID Inc., one of the world’s leading software companies delivering data center composability, announced today a new case study with Durham University in Durham, England, describing its deployment of Liqid composable disaggregated infrastructure (CDI) software. Durham University is home to the COSmology MAchine (COSMA) operated by the Institute for Computational Cosmology (ICC) and is a national supercomputing facility that is part of the UK’s Distributed Research utilizing Advanced Computing (DiRAC) system. Liqid Matrix™ CDI software is part of a system used to study the origins of the universe, composing disaggregated GPUs in a tight footprint designed for a more sustainable digital architecture. With the ability to grow as resources are needed, the Liqid system will help researchers in the UK and around the world unlock the mysteries of the 14 billion-year history of the cosmos with far greater speed and efficiency than traditional data center systems.

“We are honored to work with institutions like Durham University and COSMA researchers to provide the resources to better explore the most profound questions in science,” said Sumit Puri, CEO & Cofounder, Liqid. “By providing the kind of software-defined data performance and architectural flexibility for powerful GPU, Liqid is enabling research breakthroughs that would have been impossible with traditional, static data center architectures so scientists can focus on results instead of waiting for resources and performance to become available.”

Liqid Matrix CDI Delivers Big Bang for Cosmologists with Adaptive, Efficient Architecture

“Durham University is using cutting-edge CDI to accelerate research, improve resource utilization, and reduce the university’s carbon footprint,” said Alistair Basden, technical manager for the DiRAC Memory Intensive Service at Durham University, who was interviewed for the case study entitled Durham University’s Institute for Computational Cosmology Accelerates Results with Composability from Liqid .

The COSMA memory-intensive system is designed specifically to support the largest cosmological simulations, most notably running simulations starting with the Big Bang and propagating through the entire history of the universe. Each simulation of dark matter, dark energy, black holes, galaxies and other structures in the universe often takes months to run, followed by long periods of data analysis.

While all of the applications deployed by DiRAC are memory intensive, valuable GPU resources are required for some of its most challenging simulations and analysis. Durham University chose Liqid Matrix software-based composable system in order to be able to share and scale GPUs in the exact amounts required for any given workload. Once the workload has been completed, GPU resources can be redistributed through Liqid Matrix software for use by other applications.

“It would be wasteful for us to populate all our nodes with GPUs,” Basden said in an interview for the case study. “Instead, we have some fat compute nodes and a login node, and we’re able to move GPUs between those systems. Composing our GPUs gives us flexibility with a smaller number of GPUs. We can individually populate the servers with one or more GPUs as required at the click of a button.”

Durham University IT is also deploying Liqid Matrix-based systems as an element of its overall strategy for a more sustainable IT ecosystem. Software-based composability enables users to do more with less, increasing efficiency and curtailing the need for physical space to store the hardware while providing significant reductions in cooling and water requirements.

“Rather than populating all our servers with GPUs, we can compose the resources we need to each server. That reduces our carbon footprint,” said Basden.

To learn more about Liqid’s academic deployments, review Liqid’s case study outlining the company’s work with the University of Illinois at Chicago’s Electronic Visualization Laboratory . Schedule an appointment with an expert on solutions based on Liqid Matrix ™ CDI software-based and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.

About Liqid Inc.

Liqid’s composable infrastructure software platform, Liqid Matrix ™, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT professionals can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.

Social Media:

https://www.facebook.com/WeAreLiqid/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye